Furthermore, for patients requiring additional reduction of LDL-C, such as in atherosclerotic cardiovascular disease or familial hypercholesterolemia, PCSK9 inhibitors have been approved [13]. Here, PCSK9 is linked to familial hypercholesterolemia.